

Press Release

FIRST INVESTMENT OF EARLYBIRD HEALTH-TECH-FUND

- **Atlantic Therapeutics Ltd. receives € 15m in funding round led by Seroba Life Sciences and Earlybird Health-Tech**

Berlin, Dublin, March 1st 2017 - Atlantic Therapeutics Group Ltd, the medical device developer of non-invasive pelvic floor strengthening and nerve stimulation products, has successfully completed a €15 million financing round, enabling it to move forward with its next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence.

The funds come from a combination of venture capital investment from Seroba Life Sciences and Earlybird Venture Capital, as well as loan capital from Silicon Valley Bank. Dr Daniel O'Mahony from Seroba Life Sciences and Thom Rasche from Earlybird Venture Capital now join the board of Atlantic Therapeutics.

Atlantic Therapeutics has spun-out from its previous owner, Bio-medical Research Group Ltd (BMR), which retains a minority shareholding. The capital enables Atlantic Therapeutics to accelerate growth from its INNOVO® technology platform via market and geographic expansion and new product development.

Steve Atkinson, CEO of Atlantic Therapeutics, said: "To have attracted such highly respected companies as Seroba, Earlybird and Silicon Valley Bank is a strong endorsement of INNOVO®. We have the opportunity to transform the lives of millions of people who suffer the stigma of bladder weakness by restoring their pelvic floors without the need for surgery, injections, lasers or intrusive devices and therapies."

"We will use this capital to accelerate the growth of our INNOVO® business with current and future generations of the product, to conclude our clinical study in support of an FDA submission for US regulatory clearance, and to conduct further trials to expand the use of our technology to other indications."

Thom Rasche, Partner at Earlybird in Berlin, Germany, said: "We are very proud to announce the investment in Atlantic Therapeutics, especially as it's our first in the new Earlybird Health-Tech-Fund. INNOVO® has the potential to overcome the taboo of bladder weakness and become an international standard of care. As well as financial support, we hope that our experience and know-how in the medical device market will be beneficial to grow Atlantic Therapeutics."

Press Release

About Atlantic Therapeutics

Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. INNOVO® from Atlantic Therapeutics is a unique, externally applied, patented CE device that delivers a safe, clinically effective and comfortable therapy to treat reversible clinical conditions associated with pelvic floor weakness in the comfort of the user's own home. Learn more at: <http://www.restorethefloor.com/>

About Earlybird Venture Capital

Earlybird is a venture capital firm focused on European technology companies, both in Health Tech & Tech. Founded in 1997, Earlybird invests in all growth and development phases of a company, offering its portfolio companies not only financial resources, but also strategic and entrepreneurial support, including access to an international network and capital markets. Learn more at: <http://www.earlybird.com/>

Presscontact: Catrin Schmidt, +49-30-467247020, press@earlybird.com